Agios

$45.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (+0.66%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours

Why Robinhood?

You can buy or sell Agios and other stocks, options, and ETFs commission-free!

About AGIO

Agios Pharmaceuticals, Inc. Common Stock, also called Agios, is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA. The listed name for AGIO is Agios Pharmaceuticals, Inc. Common Stock.

CEO
Jacqualyn A. Fouse
Employees
536
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
3.16B
Price-Earnings Ratio
Dividend Yield
Average Volume
484.88K
High Today
$46.38
Low Today
$45.01
Open Price
$45.61
Volume
487.21K
52 Week High
$56.75
52 Week Low
$27.77

Collections

AGIO News

BenzingaNov 20

Unusual Options Activity Insight: Agios Pharmaceuticals

On Friday, shares of Agios Pharmaceuticals (NASDAQ: AGIO) saw unusual options activity. After the option alert, the stock price moved up to $42.75. Sentiment:

AGIO Earnings

-$1.87
-$1.25
-$0.62
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 11, Pre-Market

You May Also Like